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Streptococcal M proteins are antiphagocytic molecules varying immunologi- 
cally from type to type while maintaining an identical biological effect. The 
virulence of  the group A streptococcus is directly related to the presence of  the M 
antigens on the cell surface and resistance to infection by these organisms is 
dependent on the presence of opsonic antibodies directed towards the M mole- 
cules. Various methods such as latex agglutination (1), hemagglutination (2, 3), 
complement fixation (4), mouse protection (5), capillary precipitation (6), long- 
chaining tests (7), and radioimmunoassays (8, 9), have been used to determine 
the immune response to the  M antigens.  Despite this  variety of alternative 
methods,  the  only generally acceptable  and  reliable  measurement of type- 
specific opsonic antibodies in the serum is the standard bactericidal test (5). The 
occurrence of cross-reactions has precluded the replacement of the cumbersome 
bactericidal assay for the measurement of type-specific immunity to streptococ- 
cal infection with one of the other in vitro techniques. 
The reason for these difficulties may be twofold: (a) the state of the M antigen 
used in the assay, and (b) the inherent nature of the protein antigen itself. The 
occurrence of cross-reactions has usually been attributed to unrelated antigens 
physically or chemically associated with the M protein (10-12). Although the M 
preparations used in  many of these studies  may well have contained other 
cellular antigens,  an  alternate explanation for these cross-reactions may be 
based on the presence of common regions in the polypeptide chain of certain M 
types (13-16). 
In the present communication, a  radioimmunoassay and solid-phase radi- 
ocompetitive inhibition experiments are used to examine the antibodies devel- 
oped against M6 protein in both human beings and hyperimmunized  rabbits. By 
these techniques, the nature of a type-specific opsonic response and its relation 
to cross-reactions were examined on a molecular level. 
Materials and Methods 
M  Protein.  Purified antiphagocytic M6-protein molecules were prepared as previously de- 
scribed (17) from detergent-extracted streptococcal cell walls. 
* These studies were supported by U. S. Public Health Service grants AIl1822 and HL03919. 
Recipient of a New York Heart Association Senior Investigatorship. 
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Indirect Bactericidal  Test.  Bactericidal test procedures and analysis of results were as de- 
scribed previously (17). Results were scored as follows: <100 colonies = 4+ opsonic antibodies, 101- 
500 colonies =  3+, 501-1,000 colonies =  2+, >  1,000-partially laked =  1+, laked plate =  0. 
Antisera.  Type-specific antisera were prepared in rabbits by inoculation of whole, heat-killed 
streptococcal vaccines  (18).  Unabsorbed and absorbed antisera were  prepared as  described by 
Retta et al.  (18). 
Human type 6 antiserum was from an individual who had high titer opsenic antibodies to type 6 
streptococci. This individual had no history of rheumatic fever or nephritis. 
Antisera against  purified  M  protein was  prepared  by  inoculation of 100  ~g  of M6 protein 
(antiphagocytic molecular form  [17])  in complete  Freund's  adjuvant at multiple  sites  in  New 
Zealand red rabbits. Rabbits were boostered intravenously I and 2 mo after the initial immuniza- 
tion  with  100  ~tg of alum-precipitated  M  protein.  Rabbits were  bled 2  wk  after each booster 
immunization and at monthly intervals thereafter. 
Radioimmunoassay  (RIA)~:  Purified streptococcal M protein (20/~g/l"00 ~1) was labeled with 
~sI by the chloramine-T method of Greenwood et al.  (19) with modifications by Gotschlich et al. 
(20). Labeled protein was separated from free '~5I by passing the solution over a 0.7 x 30-cm column 
of Sephadex G-10 equilibrated with phosphate-buffered saline at pH 7.4.  12~I-Labeled  M  protein 
was adjusted to a concentration of 300 ng/ml in 1% bovine serum albumin (BSA) and used in a Farr 
antigen-binding assay employing 40% saturation of ammonium sulfate (saturated at room temper- 
ature) to precipitate the immune complex (21).  The double-label technique of Gotschlich (22) was 
employed. All sera were heat-inactivated for 30 min at 56°C and, when necessary, serum dilutions 
were performed in heat-inactivated fetal calf serum (FCS). Volumetric measurements were done 
with either Eppendorf pipettes (Brinkmann Instruments, Inc., Westbury, N. Y.) or with the use of 
an automatic pipette system (Micromedic Systems, Inc., Horsham, Pa.).  All tests were done in 
duplicate and binding results varying >5% between duplicates were repeated. 
Briefly, to a microtiter plate (Linbro IS MVC 96, Linbro Chemical Co., New Haven, Conn.) was 
added 10/~1 of test serum or a dilution thereof, 20 ~l ofl% bovine serum albumin, and 10 ~1 of 12sI- 
labeled M  antigen containing 2'Na. After equilibration overnight at 4°C,  40/~1 of 80% saturated 
ammonium sulfate (saturated at room temperature) was added and the plate placed at 4°C for 1 h. 
At this time, the precipitate was centrifuged for 20 min at 1,600g and the majority of the supernate 
removed  and  counted  in  a  Packard  two-channel  gamma  spectrometer  (model  3022,  Packard 
Instrument Co., Inc., Downers Grove, Ill.) with one channel set to count "Na and the other, ~I. 
The iodine count represents the antigen remaining unbound in the supernate in relation to the 
22Na counts.  With these data, the exact amount of antigen bound to antibody can be calculated 
(22). 2 
Solid-Phase Radiocompetitive Inhibition.  To determine if different immune sera would com- 
pete for the same or different sites on the M antigen, human serum or rabbit immune serum was 
bound to N-hydroxy-succinimide-activated Sepharose  3 (23). The beads were diluted such that 20/zl 
would bind between 90 and 100% of the radiolabeled M antigen at a concentration of 100 ng/ml. To 
a  microtiter plate 20 ~l of serum or a  dilution thereof, which was to act as inhibitor, was mixed 
with 20  ~tl of 125I-labeled  M  protein in  1%  BSA containing 22Na as  a  volume marker and the 
mixture allowed to stand at room temperature for 1 h. To this was then added 20 pl of Sepharose 
beads bound with the appropriate serum. The plates were sealed and agitated on a Boerner shaker 
at 4°C for 48-72 h. At this time, the beads were sedimented at 300g for 10 rain and the m~jority of 
the supernate  removed and counted.  The bindings were  calculated  as  described above  (RIA). 
Percent inhibition was calculated from the binding observed in control tubes containing FCS or 
normal rabbit serum as inhibitor. Results were expressed as percent inhibition, calculated from 
the formula:  100  x  (total antigen bound  -  total antigen bound in presence of inhibitor)/total 
antigen bound. As with the RIA, all tests were performed in duplicate and results varying >  5% 
between  duplicates  were  repeated.  All  inhibitions were  repeated  at  least  twice  on  separate 
occasions to assure consistency of results. 
1  Abbreviations  used  in this paper:  BSA, bovine serum albumin; FCS,  fetal calf serum; RIA, 
radioimmunoassay. 
2 Gruse, A., and E. C.  Gotschlich. Manuscript in preparation. 
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Antigen-Antibody Dissociation Analysis.  The stability of the ~2SI-M-anti-M complex was de- 
termined from the rate of dissociation of the complex by a modification of the procedure described 
by Grey (8). To wells in a microtiter plate was added 10 pl of radiolabeled M6 protein at 300 ng/ml, 
containing 22Na as a  volume marker (22),  20 pl 1% BSA and 10 pl of antiserum. The antiserum 
concentration was such that 10 ftl would bind --80%'of the antigen in the system. For each serum 
tested, five sets of duplicates were prepared which were allowed to equilibrate overnight at 4°C. At 
this time,  10  ~1  of unlabeled M6  protein was  added  to  each well  at  a  100-fold excess of the 
radiolabeled M6 protein. At timed intervals (0, 1, 2, 4, 8, 24 h) after the addition of the excess M 
protein, 50 ~1 of 80% saturated ammonium sulfate (saturated at room temperature) was added to 
each set. The plates were then mixed, allowed to stand at 4°C for 1 h, and then centrifuged at 1,600 
g  to sediment the precipitate. 
An aliquot of the supernate was removed, counted, and the percent of ~2SI-M6 protein bound 
determined as described above (R/A). Percent dissociation was calculated by the formula: 
%ppt  4 (time ×) -  %ppt (FCS  s) 
% dissociation =  ×  100. 
%ppt (time 0) -  %ppt (FCS) 
Absorption of Type-Specific Precipitating Antibodies.  Type  6  opsonic rabbit serum  was  ab- 
sorbed to remove only the type-specific precipitating antibodies as previously described (17).  120 
~g of type-specific M-protein molecules bound to activated Sepharose (23) was added to 1 ml of 
hyperimmune M6 opsonic rabbit serum and the mixture rotated end over end at 4°C for 18 h. The 
beads were then sedimented at 1,500g for 10 rain and 0.5 ml of the absorbed serum was removed 
and reabsorbed with 60 ~g of M protein under the same conditions as the first absorption. Serum 
absorbed in this way exhibited no precipitating reactivity by Ouchterlony or capillary precipita- 
tion with M6 protein. The absorbed serum however, maintained its opsonic activity in the indirect 
bactericidal test. 
Results 
Human Antibody Response to M Protein Measured by RIA.  In contrast to 
acid-extracted M protein which precipitates with as little as 33% saturation of 
ammonium sulfate (16, 24, 25), detergent-extracted M protein will not begin to 
precipitate until a  saturation of 60% has been attained.  Taking advantage of 
this  characteristic,  purified  antiphagocytic  e  M6-protein  molecules  (17) were 
radiolabeled and utilized in an RIA using 40% saturation of ammonium sulfate 
to precipitate the immune complex (21). It was found that over a limited range 
(25-80% binding),  a linear relationship exists between the percent of radiola- 
beled antigen bound and the logarithm of the antibody concentration for both 
human serum containing type 6 antibodies and rabbit type 6 immune serum. 
Using this immunological tool, we attempted to determine whether binding 
could be correlated with the presence of opsonic antibodies in human serum. 24 
human  sera  ~ were separated  into two groups:  10 sera containing  no opsonic 
antibodies against type 6 streptococci, and 14 sera with opsonic antibodies, as 
measured by the indirect bactericidal assay employing normal human blood. 
When these sera were analyzed in the antigen-binding assay for their ability to 
bind radiolabeled M6 protein at 300 ng/ml (Fig. 1), all except two of those sera 
which had no opsonic antibodies bound <25% of the radiolabeled M6 antigen. 
Those sera containing type 6 opsonic antibodies bound between 40 and 80% of  the 
4 % ppt stands for percent counts in precipitate. 
5 FCS for human system and normal rabbit serum for rabbit system. 
e Antiphagocytic molecules represent those M-protein molecules able to absorb opsovic antibod- 
ies from type-specific opsonic sera (17). 
7 Some of these sera which were from individuals involved in a  type-6 outbreak,  were kindly 
supplied by Dr. Jean P.  Widdowson, Cross-Infection Reference Laboratory, London, England. VINCENT  A.  FISCHETTI 
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FIG.  1.  Comparison between M6 opsonic and nonopsonic serum and their ability to bind 
12~I-M6 protein in an RIA. 0 signifies no detectable opsonic antibodies to M6 streptococci in 
the indirect bactericidal test. Sera E. D. and M. S. were also tested in the direct bactericidal 
assay.  +  Signifies the presence of opsonic antibodies measured in the indirect bactericidal 
test. 
radiolabeled M6 protein. Therefore, except for the two sera which had no opsonic 
antibodies  s yet bound  44  and  75%  of the  radiolabeled M6  antigen,  a  direct 
correlation could be seen between binding and the presence of opsonic antibodies 
to M6 streptococci. 
The Relationship between Binding and Opsonic Antibodies.  Further stud- 
ies were designed to determine the nature of the binding of those sera which had 
no M6 opsonic antibodies yet bound the type 6 M-protein molecule (Fig.  1).  It 
was postulated that these two sera might contain antibodies against the type- 
specific portion or cross-reactive sites  of the M  protein,  but not towards the 
antiphagocytic moiety of this  M  antigen  (17). To test this hypothesis,  high- 
titered human M6  opsonic  serum was  bound to N-hydroxy-succinimide-acti- 
vated Sepharose beads (23), and its ability to bind the radiolabeled antiphago- 
cytic M6 protein was inhibited with varying concentrations of soluble opsonic 
sera as well as those sera which exhibited binding but no opsonic activity. As 
can be seen in Fig. 2, when binding of the M6 protein to the antibodies on the 
Sepharose beads was tested in the presence of various M6 human opsonic sera, 
79-95% inhibition was observed at the highest serum concentration of all sera 
tested. These results indicate that nearly the complete complement of antibodies 
directed against the M6 molecule present in the solidified opsonic serum was 
also present in the soluble heterologous human opsonic sera. However, when the 
nonopsonic binding sera were used to inhibit the reaction, (Fig. 2, broken lines), 
only 25 and 9% inhibition was observed at the highest serum concentration, 
s These sera were tested in both the direct and indirect bactericidal tests. 1112  STREPTOCOCCAL  M  PROTEIN  EXTRACTED  BY  NONIONIC  DETERGENT 
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Competitive inhibition of binding of 125I-M6 protein to human opsonic serum (V. 
) and nonopsonic 
suggesting that these sera lacked the complete complement of antibodies pres- 
ent in the opsonic sera. 
The reciprocal experiment was also performed, in which one of the nonopsonic 
binding sera (E. Do) was immobilized on Sepharose beads, and its ability to bind 
the M6 protein inhibited with human opsonic serum as well as the homolgous 
nonopsonic binding  serum  (Fig.  3).  As  can  be  seen,  both  the  heterologous 
opsonic  serum,  along  with  the  homologous  nonopsonic  serum,  completely 
blocked the binding of the M6 protein to the nonopsonic serum on the beads. 
These results taken with the previous experiments suggest that the opsonic 
serum contains a  population of antibodies not present in the nonopsonic but 
binding serum. The data are also consistent with the view that the antiphago- 
cytic M-protein molecule contains multiple antigenic determinants (17), and 
only those antibodies directed against certain sites on the molecule are able to 
neutralize the antiphagocytic property of the antigen. To strengthen this hy- 
pothesis, similar experiments were performed  with hyperimmune  rabbit sera. 
A battery of unabsorbed hyperimmune rabbit antisera directed against the 
heterologous streptococcal M  types were  analyzed for their  ability  to  bind 
radiolabeled M6 protein in the RIA. It was found that 43% of these heterologous 
sera at a  hll dilution were able to bind the M6 antigen (Fig.  4),  while 20% 
continued to  bind  this  antigen  at  a  1:44 dilution.  The  homologous type  6 
antiserum, however, bound >95% of  the antigen at all these dilutions. When the 
cross-reactive sera were tested for their ability to precipitate the M6 protein or 
opsonize type 6 streptococci in a bactericidal test, they were found to be unreac- 
tive. Results such as these indicate that the cross-reactive sera contain antibod- 
ies directed against portions of the M6 molecule having regions in common with 
the cross-reactive M type, which does not encompass the antiphagocytic moiety. 
To determine the percent of the M6 molecule responsible for these cross-reac- 
tions  with  relation  to  the  homologous M6  response,  competitive inhibition 
experiments were performed. Various  M6  rabbit  antisera,  as  well  as  those 
heterologous sera which exhibited cross-reactions with the M6 molecule at 1:44 VINCENT  A.  FISCHETTI  1113 
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FIG. 3.  Competitive  inhibition  of binding of 125I-M6 protein to nonopsonic binding  serum 
(E. D.) on Sepharose beads. Serial  dilutions  of the homologous nonopsonic binding serum 
(E.  D.),  heterologous opsonic  serum  (V.  F.),  and normal human serum  were  used  as 
inhibitors. 
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FIG. 4.  Binding ~25I-M6  protein in an RIA with  1:11, 1:22, and 1:44 dilutions of unabsorbed 
heterologous rabbit  sera.  Numbers signify M types of those  sera  binding a  significant 
amount of the M6 protein. 
dilution (Fig. 4), and several sera exhibiting little or no cross-reactions even at a 
1:11  dilution were  used  to compete  with  the  solidified  M6  antiserum  for  the 
antigenic sites on the radiolabeled M6 protein. 
In the first experiments, M6 opsonic rabbit serum (R1940) was immobilized on 
Sepharose and dilutions of various M6 opsonic sera were used to compete for the 
binding of the radiolabeled M6 protein to the immobilized antibodies. As can be 
seen in Fig.  5, when high-titered  (R1940 and R1941) and lower-titered  (R4573) 
opsonic antisera  prepared in different rabbits  against whole  M6 streptococcal 
vaccines were used as competitors, >95% inhibition was observed at high serum 
concentrations. Similarly, when a lower-titered opsonic serum prepared against 1114  STREPTOCOCCAL  M  PROTEIN  EXTRACTED  BY  NONIONIC  DETERGENT 
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FIo.  5,  Competitive inhibition of binding of 1251-M6 protein to solidified M6 opsonic rabbit 
serum  (R1940) with various M6 opsonic sera.  Serial dilutions of high-titered M6 opsonic 
rabbit sera (R1940 and R1941) and low-titered serum (R4573) prepared with whole strepto- 
coccal vaccines were used as inhibitors. Dilutions of a  lower-titered opsonic serum  (Rll) 
prepared by immunization with purified M6 protein was also used to inhibit binding of the 
M6 antigen to  the  antibodies on the Sepharose  beads.  Homologous  signifies the  serum 
which was bound to the beads and was also used as the soluble antiserum inhibitor. 
purified M6 protein (Rll) was used as a  competitor, over 85%  inhibition was 
observed up to a  1:8 dilution. On the other hand, as seen in Fig. 6, when the 
heterologous cross-reactive rabbit antisera were used to compete for the sites on 
the M6 protein, only partial inhibition was observed in all cases. Despite the fact 
that M47 antisera had a high titer of cross-reactive antibodies (89%) against the 
M6 antigen in the binding assay (Fig. 4), these antibodies were directed to ~40% 
of the determinants recognized by the homologous M6 antibodies on the Sepha- 
rose beads.  In contrast,  M14  and M5 antisera,  which bound ~80% of the M6 
antigen in the RIA (Fig. 4), could compete for only =--15% of the sites on the M6 
molecule. Similar results were also observed with M46 antiserum which blocked 
nearly 18% of the sites. Also evident from these data is the fact that several sera 
contain relatively high concentrations of cross-reactive antibodies, where multi- 
ple dilutions were required before a drop in titer was initiated. T36 antiserum, 
on the other hand, had high cross-reactive antibodies at high serum concentra- 
tions (Fig. 4) which could compete for the majority of the M6 sites. However, the 
level of these antibodies was  low as  demonstrated by the rapid  drop in the 
dilution curve (Fig. 6). As expected, those sera which had little or no binding of 
the  M  antigen  in  the RIA  (M38  and  M42,  as  random representatives)  also 
exhibited no inhibitory effect. 
These results corroborate the data obtained with the human sera, indicating 
that  opsonic  serum contains  a  spectrum of multispecific antibodies directed 
against multiple antigenic sites along the M-protein molecule. In this spectrum, 
however, antibodies directed towards certain antigenic determinants seem to be 
necessary for opsonization.  Cross-reactive antibodies, on the other hand, bind 
only to limited determinants on the M-protein molecule which do not seem to 
affect the antiphagocytic characteristic of the protein. VINCENT  A.  FISCHETTI  1115 
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FIG.  6.  Competitive inhibition of binding of 1=5I-M6 protein to solidified M6 opsonic rabbit 
serum with heterologous cross-reactive rabbit  sera.  Serial dilutions of rabbit sera cross- 
reactive in the RIA (Fig. 4) were used as inhibitors. M6 antiserum was the positive control 
and noncross-reactive sera M38 and M42 were negative controls. 
Opsonic Antibodies vs. Binding in the General Population:  Since the above 
experiments on human sera were performed with sera from laboratory person- 
nel and individuals with known M6 infections, the results may not reflect a true 
picture of the actual immune mechanisms involved; therefore, human sera from 
the  general population  were examined in  a  similar  manner.  Sera  from  76 
Trinidadian children, 5-12 yr of age, were tested for the presence of M6 antibod- 
ies by the RIA, screened for the presence of opsonic antibodies, and tested for the 
ability to compete against M6 opsonic serum for the antigenic sites on the M6 
antigen. Fig. 7 illustrates that significant binding was observed with many of 
these sera when analyzed undiluted in the binding assay. However, the ability 
of these antibodies to bind the M6 antigen was reduced nearly to nonspecific 
background levels by a 1:11 dilution of the sera. When tested for the presence of 
opsonic antibodies,  all the sera were found to be negative.  Moreover, in the 
competitive inhibition assay, those sera exhibiting significant binding (>30%, 
undiluted) inhibited <28%  of the antigenic sites on the M6 molecule with a 
mean inhibition of 10.2% (range 2.8-27.2%).  These results indicate that even 
though many of the children tested had binding antibodies to the M6 antigen, 
the antibodies were of low titer or avidity, and reactive with only few sites on 
the M6 antigen. 
A different picture was observed, however, when American adults between 
the ages of 21 and 28 were analyzed by these methods. As can be seen in Fig. 8, 
several sera contained binding antibodies to the M6 antigen which were not 
reduced by a 1:11 dilution. When the sera were tested for M6 opsonic antibodies, 
a  lack of correlation was observed when compared with the bindings of undi- 
luted sera, whereas good correlation was observed when compared with the sera 
diluted 1:11. The results indicate that except for sera 8976, 1331, 8935, 1413, and 
8958, which exhibited significant binding but contained no M6 opsonic antibod- 
ies, those sera which bound >20% of the M6 antigen at 1:11 dilution contained 
M6 opsonic antibodies. Results of the competitive inhibition experiments on the 
high- and low-binding sera are also compiled in Fig. 8. 1116  STREPTOCOCCAL  M  PROTEIN  EXTRACTED  BY  NONIONIC  DETERGENT 
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FIO.  7.  Binding of 125I-M6 protein in an RIA with sera from children in Trinidad. 76 sera 
were tested both undiluted and at  a 1:11  dilution. Horizontal line signifies the mean binding 
in  both dilutions. Mean  age was 7.2 with a range of  5-12 yr of  age. FCS binding was 8.3%. 
I00 
80 
c 
60 
-  40 
20 
£ 
t. 
4 
I,, 
% 
Serum  Opsonic  Inhibition 
Antibodies 
1:8  116 
8954  4+ 4+  77 
8976 
9027 
•  f331 
9043 
8935 
•/.  9036, J413 
~9015 
~'~8958 
•  ~  8969 
:  ~  8957 
,~8936 
o  o  7 
2+  2+  43 
0  0  5 
4+  4+  60 
il  " 
%0  0  72,7 
4+  84 
+  3+  21 
2+  4+  32 
2 +  3 +  54 
Undil  I:11 
Adult  serum 
FIG.  8.  Binding of ~2Sl-M6 protein in an RIA with sera from adults in the United States. 
Individual  sera  were  tested  both  undiluted  and  at  a  1:11  dilution.  Indirect  bactericidal 
results are tabulated individually beside those sera showing significant binding at a  1:11 
dilution. The results are expressed as the amount of opsonic antibodies present in the serum 
based on the amount of growth seen after a  3-h rotation of two dilutions of M6 streptococci 
(1:8  and  1:16),  (Materials  and  Methods).  The results of the competitive  inhibition  assay 
performed  on these sera are  also indicated.  No opsonic antibodies were  observed in  sera 
exhibiting <20% binding; inhibitions of <10% were  also observed with these low-binding 
sera.  Horizontal  bar signifies the mean binding for both dilutions. The mean age of these 
individuals was 29.1 with a  range of 21-38 yr of age. FCS binding was 8.3%. VINCENT  A.  FISCHETTI  1117 
It can be seen that those binding sera containing no opsonic antibodies could 
compete for only 11% or less of the antigenic determinants on the M6 protein. 
However, those sera with both binding and opsonic antibodies were able to block 
>20% of the sites on the M6 molecule with the majority of the sera inhibiting 
>50% of the determinants. Therefore, with the exception of sera 8969 and 8957 
which inhibited 21  and 32%,  respectively, the results are consistent with the 
results seen above; namely, that an opsonic response is demonstrated by anti- 
bodies directed against the majority of determinants on the M molecule. 
The Role  of Avidity  in  Opsonization.  In an attempt to  determine if the 
stability of the antigen-antibody complex (i.e. avidity) plays a role in promoting 
opsonization, the "off-rate" of  the M-anti-M immune complex was measured. By 
the addition of a large excess of unlabeled M antigen to an equilibrated mixture 
of radiolabelod M6 protein and various sera, the dissociation rate of the complex 
can be analyzed.  9 As can be seen in Fig. 9, when either rabbit (M6) or human 
opsonic sera (V. F. and 8954) were tested by this method, <31% of the 125I-M6- 
anti-M6 complexes dissociated within 24 h. However, when cross-reactive sera 
were examined, striking differences were observed. The cross-reactive human 
serum W84 (from Trinidad) as well as the cross-reactive rabbit sera M19 and 
M47  exhibited  >41%  dissociation within the  1st h,  indicating weak binding 
within the complex. In contrast, however, cross-reactive nonopsonic human (E. 
D.) and rabbit serum (M14) both exhibited antibody binding avidities equivalent 
to those seen in the opsonic sera. These results suggest that the avidity of an 
antibody for the M antigen is therefore not the sole factor necessary for opsoniza- 
tion. Other factors besides avidity, one of them being the site or sites bound by 
the antibody, also seem essential for opsonization to occur. 
Binding Sites Necessary for Opsonization.  In our previous publication (17) it 
was shown that absorption of type-specific opsonic serum with small molecular 
weight type-specific M-protein molecules resulted in the removal of  the ability of 
the serum to  precipitate without affecting its  opsonic power.  By using this 
selectively absorbed serum as an inhibitor in our competitive inhibition assay 
with the unabsorbed M6 opsonic serum immobilized on Sepharose, we were able 
to determine the nature of the specificity of the opsonic antibodies. The results 
presented in Fig. 10 indicate that antibodies directed towards 30% of the determi- 
nants  on  the  M6  molecule could be  removed by this  absorption  procedure, 
allowing for 70% inhibition to be observed. The data suggest therefore that the 
antibodies present in the absorbed opsonic serum were directed against up to 
70% of the determinants on the M-protein molecule. 
Discussion 
Many of the difficulties encountered by Grey (8) and Anthony (9) in the use of 
M protein in an RIA have been overcome by detergent-extracted and purified M 
protein (17). l~SI-Labeled M6 protein at a concentration of 300 ng/ml was success- 
fully used in a  binding assay using 40% ammonium sulfate to precipitate the 
immune complex.  In this  system,  <10%  of the radiolabeled M  antigen was 
8 Certain qualifications of this statement will be alluded to in the discussion. 1118  STREPTOCOCCAL  M  PROTEIN  EXTRACTED  BY  NONIONIC  DETERGENT 
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FIG. 9.  Dissociation  rates  of  ~=SI-M6-anti-M6 complexes. Opsonic  human sera (8954  and  V. 
F.) as  well as  nonopsonic binding sara (E. D. and W84) were compared with rabbit opsonic 
(M6) and cross-reactive  (M14, M19, and M47) antisera for their  binding avidities  for M6 
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FIG. 10.  Competitive  inhibition  of binding  of I~'~I-M6 protein  by selectively  absorbed 
serum. M6 opsonic rabbit  serum (R1941) was absorbed with type-specific M-protein mole- 
cules to remove the type-specific precipitating  antibodies  without  affecting the opsonic 
power of the serum  (17). The unabsorbed serum was immobilized on Sepharose and dilu- 
tions  of the homologous unabsorbed  and absorbed sera  were used  to compete with  the 
immobilized antibodies for the sites on radiolabeled M6 protein. 
bound  by  FCS  or  normal  rabbit  serum,  whereas  >95%  was  bound  by  the 
homologous type-specific rabbit antisera. 
Even though good correlation was observed between the binding capacity of 
human serum and its opsonic power in the M6 system, we have observed that VINCENT  A.  FISCHETTI  1119 
sera  of  certain  individuals  lacking opsonic  antibodies  do  contain antibodies  able 
to bind the M6 antigen. These results  prompted us to consider  the nature of  a 
type-specific  opsonic  response to  this  multideterrninant antigen with relation  to 
cross-reactions. 
Cross-reactions  in hyperimmune rabbit sera have been described  by several 
investigators (26,  27).  Cross-absorption experiments between M12 and M3 by 
Fox and Wittner (15)  indicated  that these proteins  contained areas in common 
which were responsible  for cross-reactions  in a hemagglutination assay. How- 
ever, these antibodies were not opsonic  for the heterologous type, suggesting 
that the antigenic  portions  of  these M-protein molecules responsible  for stimu- 
lating  opsonic  antibodies  was not shared.  Wittner (13),  in  a more recent  publica- 
tion, was able to separate passive mouse-protecting  and hemagglutinating 
antibodies  from opsonic antibodies  by a specialized  absorption procedure, again 
pointing to common antigenic  determinants among certain  M  proteins. 
By the use of the solid-phase radiocompetitive inhibition  experiments de- 
scribed here, the mechanism  of these cross-reactions  may be observed on a 
molecular level.  Before proceeding, however, the reader must be made aware 
that  interpretation  of  these  experiments was based on  the following  assumption: 
Since whole serum was used in the binding of  the antibodies  to the Sepharose 
beads, it  was assumed that the proximity of  one antibody to the next was such 
that an M-protein molecule could not be bound by two adjacent antibodies.  If 
this is the case (and experimental  results seem to bear this out),  then the 
binding of  a soluble  antibody molecule to an antigenic determinant on the M 
protein will  inhibit  that protein from binding to the solid-phase  antibody di- 
rected  to that determinant. 
The results presented  here support the view that the antiphagocytic M 
molecule contains multiple antigenic determinants; i.e.,  some concerned with 
type-specificity  and/or cross-reactivity,  and some with antiphagocytosis (17).  An 
antigenic structure such as this  would give rise  to a multispecific  antibody 
population in  the host.  Assuming that  the  complete complement of  antibodies  to 
the M-protein molecule is present in the opsonic  serum which is bound to the 
Sepharose beads,  the small amount of  inhibition  brought about by the binding 
but nonopsonic sera  (Fig.  2) indicates  that these sera do not contain antibodies 
to all the determinants present on the M  molecule. Since these antibodies  can 
bind only to a limited number of  sites  on the M  molecule (i.e.  type-specific  or 
cross-reactive),  then other  sites  (i.e.  antiphagocytic)  would be free  to  bind  to  the 
opsonic antibodies  on the Sepharose beads. 
In  contrast,  when opsonic  sera (Fig.  2)  were used  in  the competitive inhibition 
assay, >79% of  the antigenic determinants were blocked from binding to the 
solidified opsonic serum. These results indicate that a type-specific  opsonic 
response to the M  antigen is  manifest by the production of  antibodies  directed 
against the majority of  the antigenic  determinants of  that M  antigen. 
Binding and inhibition  experiments performed with radiolabeled  M6 protein 
on heterologous hyperimmune rabbit  sera revealed similar  results.  The major- 
ity  of  these heterologous sera  bound <20% of  the M6 antigen in a standard RIA 
while certain  sera contained antibodies  which bound >20% of  the M6 antigen 
even when diluted 1:44.  In spite  of  the presence of  high-binding cross-reactive 1120  STREPTOCOCCAL  M  PROTEIN  EXTRACTED  BY  NONIONIC  DETERGENT 
antibodies, these heterologous sera exhibited no opsonic or precipitating activity 
with the M6 system. 
Results of the competitive inhibition experiments revealed that when various 
M6 sera were used to inhibit the binding of M6 protein to the solidified M6 
opsonic rabbit serum, inhibitions of >85% were observed (Fig. 5). This amount 
of inhibition was consistent regardless of the type of M antigen used to raise the 
antibodies (i.e., whole streptococcal vaccine or purified M protein). In contrast, 
the heterologous cross-reactive sera were only able to compete for a  limited 
number of determinants along the M6 molecule (Fig.  6) in spite of the high 
binding capacity of some of these sera (i.e., M47, M46, M14, M5, Fig. 4). Again, 
these results suggest that the antiphagocytic moiety of the M antigen is re- 
stricted to certain determinants along the molecule. Even though ~50 and 70% 
of the M6 determinants were bound by M47 and M36 antisera respectively, the 
sites responsible for the antiphagocytic effect were not affected by these two 
heterologous sera, as demonstrated by their inability to promote opsonization of 
M6 streptococci in a bactericidal test. The fact that these sera were of  low avidity 
may help to explain these results (see below). 
Turning now to the results obtained with sera gathered from the general 
population, it is well-known that children in rural areas of Trinidad are chroni- 
cally infected by group A  streptococci through impetiginous infections  (28). 
Binding experiments to measure antibodies to type 6 streptococcal M protein 
revealed that even though M6 streptococcal infections are extremely rare in 
Trinidad,  the majority of these sera when tested undiluted, had significant 
binding antibodies to this protein. However, a  1:11 dilution of the sera nearly 
reduced the binding to base-line levels (Fig. 7). On the other hand, none of the 
sera contained opsonic antibodies to M6 streptococci when tested in the bacteri- 
cidal test.  Moreover, when tested in the competitive inhibition experiments, 
even those  sera  which had  high  cross-reactive antibodies  exhibited limited 
inhibition of the M6 antigen (<25%),  suggesting that the M antigen of strains 
endemic to Trinidad may contain regions in common with the M6 antigen. The 
fact that the binding can be reduced by a 1:11 dilution of the serum suggests that 
these antibodies are of low titer and/or low avidity. 
In contrast, several adult sera from individuals in the United States exhibited 
substantial binding to the M6 antigen when tested both undiluted and at a 1:11 
dilution. When the sera were tested for opsonic antibodies to M6 streptococci, 
most of the  sera  which bound  >20%  of the antigen at  a  hll  dilution also 
contained opsonic antibodies. However, as in our previous results (see above), 
some of the sera which bound the M antigen did not contain opsonic antibodies. 
When the sera were tested by the competitive inhibition experiments, those 
with opsonic M6 antibodies inhibited >20% of the homologous reaction with the 
majority of these sera inhibiting >50%  of the sites on the M antigen. On the 
other hand, the nonopsonic binding sera could only inhibit <12% of  these determi- 
nants. As with the rabbit sera results, these data again suggest that an opsenic 
response to the M antigen is represented by the production of antibodies to the 
majority of the antigenic determinants on the M molecule. 
The determination of the avidity of a particular serum by measuring the "off- 
rate" of an immune complex is a difficult problem when dealing with a multide- VINCENT  A.  FISCHETTI  1121 
terminant antigen.  RIA  methods used  here  in  separating bound from free 
antigen (i.e. precipitation with ammonium sulfate) score an antigen as "bound" 
whether it has one or more antibody molecules bound to it and score it "free" 
only if no antibodies are bound. By this method, one can distinguish only two 
over-all states of the whole antigen; either "free" with no antibodies bound or 
"bound" with one or more of the antigenic determinants bound by antibody. 
Realizing this limitation, it was still quite evident that the avidity of  the opsonic 
sera was substantially greater than those which were nonopsonic. It was also 
evident from these results that certain nonopsonic sera (E. D. and M14, Fig. 9) 
had at least one antibody whose avidity was equivalent to that found in the 
opsonic sera. This suggests that an antibody must possess special characteristics 
other than high avidity before it can be capable of opsonization. Grey (8) in 1962 
observed similar dissociation rates on sera from rabbits immunized with group 
A  streptococci. However, since no bactericidal tests were performed on these 
sera, direct comparisons with our results cannot be made. 
Additional information concerning the sites bound by the opsonic antibodies 
was revealed by the competitive inhibition results using selectively absorbed 
sera. It was determined from these experiments that the type-specific  precipitat- 
ing antibodies present in rabbit serum were directed towards only 30% of the 
antigenic determinants on the  M6  molecule whereas the remaining opsonic 
antibodies reacted with  up  to  70%  of the  sites.  These results  indicate that 
multiple antigenic determinants situated along the M-protein molecule must be 
bound by specific antibodies before opsonization occurs. 
One can see by the results presented that a type-specific opsonic response to 
an M antigen is represented by the production of antibodies directed against the 
mosaic of antigenic determinants which comprise this antigen. The results also 
suggest that opsonization is not prompted by the mere binding of antibodies to 
the M antigen, but necessitates the binding of avid antibodies to a number of 
type-specific antiphagocytic determinants on the antigen. Furthermore, results 
of the competitive inhibition experiments on both rabbit and human opsonic 
sera indicate that an opsonic response is generally demonstrated by antibodies 
directed against the  majority of the determinants on the M  molecule. This 
suggests that the production of opsonic antibodies may be the culmination of  the 
response to the antigen. Whether this is strictly a quantitative or qualitative 
effect is presently under investigation. Cross-reactive antibodies, on the other 
hand, are directed against a limited number of antigenic determinants and do 
not possess opsonic activity. If carefully and systematically  utilized, these cross- 
reactions, in conjunction with structural data,  may enable us to understand 
more clearly the relation between various M  types and the nature of their 
antigenic shifts (29). 
Summary 
Purified streptococcal M protein extracted by nonionic detergent was used in 
an RIA and a  solid-phase radiocompetitive inhibition assay to determine the 
nature of the immune response in both human beings and hyperimmunized 
rabbits to this complex antiphagocytic antigen.  Results indicate that a  type- 
specific response to an M antigen with the development of opsonic antibodies is 1122  STREPTOCOCCAL  M  PROTEIN  EXTRACTED  BY  NONIONIC  DETERGENT 
the result of antibodies directed against the majority of the antigenic determi- 
nants  of the  molecule.  Cross-reactions  between  certain  M  types on the  other 
hand, are represented by antibodies directed against only a  small percentage of 
these antigenic determinants.  Results also suggest that avidity may play a role 
in  the  action  of opsonic  antibodies.  However,  the  data  indicate  that  factors 
besides  avidity  (i.e.  sites  bound  by  the  antibodies)  also  seem  essential  for 
opsonization. 
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